Myelodysplastic syndromes trials in France

In France 50 Also abroad 368

50 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Marseille, Pierre-Bénite, Toulouse, Tours
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Where
Nice, Paris, Poitiers, Toulouse Cedex 9
Age
18 years and over
People
225 worldwide
Run by
Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00
Phase 3Taking people
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Where
Grenoble Cedex 9, Nice, Paris, Poitiers, Villejuif
Age
18 years and over
People
300 worldwide
Run by
Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 1Taking people
Study of REM-422 in Patients With AML or Higher Risk MDS
Where
Bordeaux, Paris, Toulouse, Villejuif
Age
18 years and over
People
100 worldwide
Run by
Remix Therapeutics
See details and how to joinNCT06297941
Phase 1Not yet taking people in France
Bioavailability and Bioequivalence Study of Ziftomenib in Participants with Relapsed/Refractory AML or MDS
Where
Lille, Pessac, Pierre-Bénite, Villejuif
Age
18 years and over
People
107 worldwide
Run by
Kura Oncology Inc.
See details and how to join2025-524332-19-00 · EU 2025-524332-19-00
No phaseTaking people
Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Where
Marseille
Age
18 years and over
People
70
Run by
Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06886425
Phase 2Taking people
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
Where
Bordeaux, Paris, Poitiers, Villejuif
Age
18 years and over
People
90 worldwide
Run by
Faron Pharmaceuticals Ltd
See details and how to joinNCT07672769 · EU 2026-526706-33-00
Phase 2Taking people
Momelotinib in VEXAS syndrome
Where
Angers, Clermont-Ferrand, Grenoble Cedex 9, Lille, Lorient, Nantes, Paris, Paris Cedex 12, Pessac, Pierre-Bénite, Rennes Cedex 9, Toulouse, Tours Cedex 9
Age
18 years and over
People
57
Run by
Groupe Francophone Des Myelodysplasies
See details and how to join2024-519779-24-00 · EU 2024-519779-24-00
Phase 2Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Where
Nantes, Nice, Paris, Pessac, Pontoise
Age
18 years and over
People
210 worldwide
Run by
Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00
Phase 2Taking people
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Where
Lille, Paris, Pierre-Bénite, Poitiers, Toulouse
Age
18 years and over
People
156 worldwide
Run by
Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00
Phase 1Taking people
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Where
Toulouse Cedex 9, Villejuif
Age
18 years and over
People
69 worldwide
Run by
Auron Therapeutics, Inc.
See details and how to joinNCT06846606 · EU 2025-521394-13-00
Phase 3Taking people
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Where
Angers, Le Mans Cedex 9, Limoges, Nantes, Nantes Cedex 2, Nice, Orleans Cedex 2, Paris, Pessac, Poitiers, Pontoise, Tours Cedex 9, Villejuif
Age
18 years and over
People
490 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00
No phaseTaking people
Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
Where
Oullins-Pierre-Bénite
Age
18 years and over
People
13
Run by
Hospices Civils de Lyon
See details and how to joinNCT06781099
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Nice, Paris, Toulouse Cedex 9
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
ANGERS Cedex 09, Grenoble Cedex 09, Nantes, Pessac, Rennes Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
No phaseTaking people
Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
Where
Angers, Bordeaux, Caen, Clermont-Ferrand, Dijon, Grenoble, Lille, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Rennes, Rouen, Saint-Priest-en-Jarez, Sèvres, Strasbourg, Toulouse, Tours, Vandœuvre-lès-Nancy
People
150
Run by
Institut Claudius Regaud
See details and how to joinNCT05983991
Phase 1/2Taking people
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Where
Amiens, Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon, Bayonne, Bobigny, Cesson Sevigne, Compiegne, Grenoble Cedex 9, Le Chesnay Rocquencourt, Le Kremlin Bicetre Cedex, Le Mans Cedex 9, Lille Cedex, Limoges, Mont-De-Marsan Cedex, Montpellier Cedex 5, Nantes, Nantes Cedex 2, Nice, Nimes Cedex 9, Orleans Cedex 2, Paris, Périgueux, Pessac, Pierre-Bénite, Poitiers, Pontoise, Quimper Cedex, Rennes, Rouen, Saint-Priest-en-Jarez, Strasbourg, Toulouse Cedex 9, Tours, Valence, Vandoeuvre Les Nancy
Age
18 years and over
People
150 worldwide
Run by
Groupe Francophone des Myelodysplasies
See details and how to joinNCT05181735 · EU 2024-515354-24-00
Phase 2Taking people
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Where
Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Nancy, Nantes, Nice, Paris, Pessac, Poitiers, Rouen, Saint-Etienne, Toulouse
Age
18 years and over
People
150
Run by
University Hospital, Clermont-Ferrand
See details and how to joinNCT04935684
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Nice, Pessac
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Paris, Poitiers, Toulouse
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Lille Cedex, Nice, Paris
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
No phaseTaking people
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Where
Rouen
Age
18 years and over
People
6,990
Run by
Groupe Francophone des Myelodysplasies
See details and how to joinNCT06956755
Phase 1Taking people
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Where
Nice, Paris, Villejuif
Age
18 years and over
People
24
Run by
Groupe Francophone des Myelodysplasies
See details and how to joinNCT06670222 · EU 2024-515311-22-00
No phaseTaking people
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Where
Nantes
Age
18 years to 99 years
People
60
Run by
Nantes University Hospital
See details and how to joinNCT06439199